An Exploratory Study of the Folic Acid-tubulysin Conjugate EC1456 in Ovarian Cancer Subjects Undergoing Surgery
An Exploratory, Open-label Study of the Folic Acid-tubulysin Conjugate EC1456 in Ovarian Cancer Subjects Undergoing Cytoreductive Surgery
Sponsor: Endocyte
A PHASE1 clinical study on Ovary Cancer, this trial is completed. The trial is conducted by Endocyte and has accumulated 10 data snapshots since 2017. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
10 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE1
-
Mar 2019 — Jan 2021 [monthly]
Completed PHASE1
Status: Active Not Recruiting → Completed
-
Aug 2018 — Mar 2019 [monthly]
Active Not Recruiting PHASE1
▶ Show 5 earlier versions
-
Jun 2018 — Aug 2018 [monthly]
Active Not Recruiting PHASE1
-
May 2018 — Jun 2018 [monthly]
Active Not Recruiting PHASE1
Status: Recruiting → Active Not Recruiting
-
Aug 2017 — May 2018 [monthly]
Recruiting PHASE1
-
Mar 2017 — Aug 2017 [monthly]
Recruiting PHASE1
Status: Not Yet Recruiting → Recruiting · Phase: NA → PHASE1
-
Feb 2017 — Mar 2017 [monthly]
Not Yet Recruiting NA
First recorded
Jan 2017
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Endocyte
For direct contact, visit the study record on ClinicalTrials.gov .